Information date: 4 September 2026 — ICH Q11, adopted by FDA, describes science- and risk-based development and manufacture of drug substances, including the relationship among starting materials, process understanding, impurity control and the overall control strategy. Knowing that statement is not enough for an operating, research or compliance decision. The team must first establish who and what it applies to, how the effect reaches the real process, and which evidence would justify action.
Verified facts and scope
ICH Q11, adopted by FDA, describes science- and risk-based development and manufacture of drug substances, including the relationship among starting materials, process understanding, impurity control and the overall control strategy.
For a synthetic peptide, sequence identity alone does not describe quality. Starting-material attributes, coupling and deprotection conditions, deletion or insertion sequences, epimerisation, oxidation, cleavage, purification, solvents and hold times can shape the impurity profile.
How the effect reaches operations
Each process step can create, remove or transform impurities. A final release test sees only what its method can separate and detect, so development must connect likely formation pathways to in-process controls and orthogonal analytics.
Tightening one final purity number without understanding co-elution may create false confidence. Changing resin, reagent, scale or purification while assuming equivalence can introduce a new impurity that the legacy method does not resolve.
For “Peptide-Synthesis Control Starts With the Process Link: Raw Materials, Impurities and Critical Steps”, official rules or published findings, direct evidence from the relevant product or process, and assumptions that remain untested should be recorded separately. A broad source defines the external boundary; it does not replace batch records, protocols, contracts, labels or direct observations.
Decision
Approve a synthesis process only when every material and critical step has a documented link to product quality and the analytical set can detect the credible impurity classes. An unexplained new peak is investigated before scale expansion.
Implementation checklist
- Build a stepwise impurity map from starting materials through cleavage, purification and storage.
- Link each credible impurity to prevention, in-process observation and at least one suitable analytical method.
- Challenge the map with one scale or material change and compare predefined quality attributes.
- Assign one decision owner, one implementation owner and a dated review point for “Peptide-Synthesis Control Starts With the Process Link: Raw Materials, Impurities and Critical Steps”.
- For “Peptide-Synthesis Control Starts With the Process Link: Raw Materials, Impurities and Critical Steps”, archive the source page, access date, applicable population or entity, and internal evidence both supporting and opposing the current decision.
- When a rule, formulation, supplier, protocol or observed result changes, reopen only the affected question in “Peptide-Synthesis Control Starts With the Process Link: Raw Materials, Impurities and Critical Steps”.
Evidence and review
For “Peptide-Synthesis Control Starts With the Process Link: Raw Materials, Impurities and Critical Steps”, start with one real case rather than an abstract checklist. Record the input version, responsible owner, start time, observed result and stop condition. If the team cannot complete “Build a stepwise impurity map from starting materials through cleavage, purification and storage.” with current evidence, it should not expand the process to more products, patients, suppliers or markets. The first review should focus only on facts capable of changing the decision.
The second control follows “Link each credible impurity to prevention, in-process observation and at least one suitable analytical method.”. Keep the source date, applicable population or entity, deadline, cost effect and owner in the same evidence file. A wording preference does not justify a new version. A repeated discrepancy, an unsupported health claim or a regulatory mismatch does: correct that point and hold release until the evidence is available.
After “Challenge the map with one scale or material change and compare predefined quality attributes.”, compare the intended outcome with what actually happened. Apply the same success criteria to each later expansion. If only one number, date or responsibility changes, update that field and the affected conclusion instead of recreating evidence that remains valid. This keeps the decision traceable without turning review into an open-ended rewrite cycle.
Limits of the conclusion
Q11 is a general development framework, not a peptide-specific acceptance specification. Exact limits and methods depend on product, route, dose, clinical context and regulatory pathway.
